In this latest instalment of the In Vivo podcast Daniel Lofaso, CEO of Digital Elevator, talks about the common mistakes biotech companies make when trying to build their brand, how to connect with varied audiences and key trends the industry should keep track of in digital marketing.

Andrew Hopkins, founder and CEO of Exscientia, invented and championed an algorithmic approach to drug design and drug discovery. He talks to In Vivo about artificial intelligence in the biopharma industry today and what lies ahead. 

Private drug developer Fabre-Kramer is expecting approval for its antidepressant gepirone hydrochloride in September 2023. The drug has been rejected multiple times by the FDA as a treatment for major depressive disorder. 

Michael White, the new UK head of life sciences at HSBC Innovation Banking, made the move from California to join the UK group shortly before Silicon Valley Bank in London collapsed in March 2023. He talks to In Vivo about turbulent life science markets and the future life sciences strategy at HSBC.

With Ipsen's recent approval of palovarotene, there have now been an estimated 65 priority review vouchers issued by the US FDA since the scheme started in 2007. Only 25 vouchers have been claimed, and the PVRs do not expire and can be sold, but the price appears to have peaked in 2015. Our infographic offers details on this regulatory mechanism.

Infographic: An estimated 64 priority review vouchers have been issued by the US FDA since the scheme started in 2007. 25 vouchers have been claimed but 39 remain unused. Priority review vouchers do not expire and can be sold.